Study Type:
Interventional[Clinical Trial]

Study Design:

• Interventional Model: Parallel Assignment
• Intervention Model Description: To assess radiographic PFS in men with mCRPC (with no systemic treatments initiated after documentation of mCRCP) treated with talazoparib and enzalutamide vs. placebo plus enzalutamide
• Estimated Enrollment: 1037 participants
• Masking: Double-blind
• Primary Purpose: Treatment

Official Title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer